MARKET

ATRA

ATRA

Atara Biotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

16.07
+0.18
+1.13%
After Hours: 16.07 0 0.00% 16:42 03/05 EST
OPEN
15.79
PREV CLOSE
15.89
HIGH
16.25
LOW
15.20
VOLUME
1.16M
TURNOVER
--
52 WEEK HIGH
28.20
52 WEEK LOW
4.520
MARKET CAP
1.34B
P/E (TTM)
-3.8184
1D
5D
1M
3M
1Y
5Y
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoim...
Business Wire · 1d ago
CAR T Cell Therapy Market 2021: Impact of COVID 19 on Industry Growth, Top Manufacture, Size, Regional Analysis and Forecast to 2026
Mar 03, 2021 (WiredRelease via Comtex) -- To be aware of the market in detail, the market research report is the perfect solution. Report such as Global CAR...
marketresearch.biz · 3d ago
Atara shares rise following Citi upgrade to biuy
Citi analyst Yigal Nochomovitz has upgraded shares of Atara Biotherapeutics, Inc. (ATRA) to buy from hold and is maintaining his $27 price target.He notes that since early December, when the
Seekingalpha · 4d ago
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA), Vir Biotechnology (VIR) and Enlivex Therapeutics (ENLV)
SmarterAnalyst · 4d ago
--Analyst Actions: Citigroup Upgrades Atara Biotherapeutics to Buy From Neutral; Price Target is $27
MT Newswires · 4d ago
DJ Atara Biotherapeutics, Inc. CEO Pascal Touchon on Q4 2020 Results -- Earnings Call Transcript >ATRA
Dow Jones · 4d ago
BRIEF-Atara Biotherapeutics Inc Files For Mixed Shelf Offering Size Not Disclosed
reuters.com · 5d ago
8-K: Atara Biotherapeutics, Inc.
(EDGAR Online via COMTEX) -- false 0001604464 0001604464 2021-03-01 2021-03-01 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATRA. Analyze the recent business situations of Atara Biotherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATRA stock price target is 33.50 with a high estimate of 78.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 229
Institutional Holdings: 90.47M
% Owned: 108.20%
Shares Outstanding: 83.61M
TypeInstitutionsShares
Increased
58
9.84M
New
47
1.63M
Decreased
43
6.08M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.94%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Ronald Renaud
President/Chief Executive Officer/Director
Pascal Touchon
Chief Financial Officer
Utpal Koppikar
Chief Operating Officer/Executive Vice President
Joseph Newell
Senior Vice President/General Counsel
K. Amar Murugan
Other
Kristin Yarema
Lead Director/Independent Director
Carol Gallagher
Senior Vice President
Kanya Rajangam
Director
Maria Roncarolo
Independent Director
Roy Baynes
Independent Director
Eric Dobmeier
Independent Director
Matthew Fust
Independent Director
William Heiden
Independent Director
Beth Seidenberg
No Data
About ATRA
Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

Webull offers kinds of Atara Biotherapeutics Inc stock information, including NASDAQ:ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.